Clinical Trial Search

Phase 3 N=82 A Trial of Corticosteroids for Low Back Pain

Radicular Low Back Pain

Primary: Numerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable — 7.1; 5.8 units on a scale

Montefiore Medical Center Results Aug 2019 0.0% serious AE View details

Phase 3 N=725 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer

Breast Cancer

Primary: Percentage of Participants With a Pathologic Complete Response — 48.0; 40.5 percentage of participants — p=0.0508

Amgen Results Aug 2019 3.7% serious AE View details

Phase 3 N=750 Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

Meningococcal Infection

Primary: Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Against Neisseria Meningitidis Serogroups Antibody Titers Greater Than or Equal to (≥)…

GlaxoSmithKline Results Aug 2019 8.4% serious AE View details

Phase 3 N=405 Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Primary: Clinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD — 28 percentage of participants

Teva Branded Pharmaceutical Products R&D, Inc. Results Aug 2019 10.9% serious AE View details

Phase 3 N=37 Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Lennox-Gastaut Syndrome

Primary: Child Behavior Checklist (CBCL) Total Problem T-scores at the End of 2-year Treatment Period — 55.7; 54.8 score on a scale — p=0.6928

Eisai Inc. Results Aug 2019 40.5% serious AE View details

Phase 3 N=295 Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Infections, Meningococcal

Primary: Number of Subjects With Serum Bactericidal Assay /Activity (rSBA) Against Neisseria Meningitidis Serogroup A, C, W-135 and Y (Using Baby Rabbit Complement) Titres ≥ the…

GlaxoSmithKline Results Aug 2019 0.7% serious AE View details

Phase 3 N=51 A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Hypoparathyroidism

Primary: Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) — 13; 48 Participants

Shire Results Aug 2019 26.5% serious AE View details

Phase 3 N=251 Web-based Smoking Cessation Program for Tribal College Students

Smoking Cessation

Primary: Number of Participants With 7-day Point Prevalence Abstinence — 9; 9 Participants

Won Choi, PhD, MPH Results Aug 2019 0.0% serious AE View details

Phase 3 N=692 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

Non-Hodgkin's Lymphoma

Primary: Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for…

Hoffmann-La Roche Results Aug 2019 47.1% serious AE View details

Phase 3 N=120 Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset

Stroke

Primary: The Percentage of Patients With Modified Rankin Scale (mRS 0-1) (Favourable Outcome) Response at Day 90 After Stroke Onset by Face-to-face Interview With Patient — 42.5…

Boehringer Ingelheim Results Aug 2019 10.0% serious AE View details

Phase 3 N=71 Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease

Coronary Artery Disease

Primary: Coronary Artery Diameter — 3.1; 2.7 mm

Imperial College London Results Aug 2019 0.0% serious AE View details

Phase 3 N=69 Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

Juvenile Rheumatoid Arthritis

Primary: Percentage of Participants With Disease Flare in Part 2 — 81; 28 percentage of participants — p=0.0030

Amgen Results Aug 2019 1.7% serious AE View details

Phase 3 N=484 Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)

Non-erosive Gastroesophageal Reflux Disease

Primary: Percentage of Days Without Symptoms of Heartburn — 61.50; 72.55 percentage of days — p=0.0643

Takeda Results Aug 2019 0.2% serious AE View details

Phase 3 N=347 European Phase III Study of APD421 in PONV

PONV

Primary: Complete Response (no Emesis, Significant Nausea or Rescue Medication) — 95; 83 Participants — p=0.093

Acacia Pharma Ltd Results Aug 2019 2.0% serious AE View details

Phase 3 N=1,899 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

Myocardial Infarction

Primary: Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. — 116; 135…

Boehringer Ingelheim Results Aug 2019 16.3% serious AE View details